New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. (&#34;Cellebrite&#34; or the &#34;Company&#34;)

<p>New York, New York--(Newsfile Corp. - August 24, 2026) - <a href="https://api.newsfilecorp.com/redirect/N3vvniN7D7">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CLBT">CLBT</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/XEOO2SPBG2">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Cellebrite investor and have suffered losses, or if you have information that could assist in the Cellebrite investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/DOWW5FnQBE"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On August 13, 2026, Cellebrite reported second-quarter results, including total Annual Recurring Revenue ("ARR") of $507.8 million, missing the lower end of the Company's previous projection for ARR in the range of $510 million to $513 million.  The Company also cut its full-year annual recurring revenue guidance by roughly $15 million at the midpoint and cited "a foreign entity permit requirement, which is applied to cloud technology" that delayed certain deals.  Cellebrite simultaneously announced an abrupt CEO change, replacing CEO Tom Hogan with Shiv Ramji, effective immediately. </p><p>Following this news, the price of Cellebrite stock fell $4.45 per share, or 29%, to close at $10.80 per share August 13, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/rpLLACq32L">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/VvLLEFYwDj">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/zA00ehyAaa">https://www.kaplanfox.com/case/cellebrite-di-ltd-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/311009_54f395c174331b48_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/4YGGLcWmqq">https://www.newsfilecorp.com/release/311009</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/311009/197" alt="" /></p>

CLBT

Kaplan Fox Notifies Cellebrite DI Ltd. (CLBT) Investors of a Securities Investigation into the Company

Cellebrite Faces Securities Investigation After Q2 Miss and CEO Change

<section class="insight" data-version="1">
  <section data-block="information">
    <h3>Information</h3>
    <p>New York, New York--(Newsfile Corp. - August 24, 2026) - Kaplan Fox &amp;amp; Kilsheimer LLP is investigating potential securities violations against Cellebrite DI Ltd. (&amp;#34;Cellebrite&amp;#34; or the &amp;#34;Company&amp;#34;)</p>
  </section>

  <section data-block="ai-summary-paragraph">
    <h3>AI Summary</h3>
    <p>Kaplan Fox &amp; Kilsheimer LLP is investigating potential securities violations at Cellebrite (CLBT) following a Q2 miss and governance shift. Cellebrite reported ARR of $507.8 million and cut full-year ARR guidance by about $15 million, while appointing Shiv Ramji as CEO. The combination of regulatory risk and leadership upheaval could pressure CLBT&#039;s valuation in the near term.</p>
  </section>

  <section data-block="ai-summary-bullets">
    <h3>Key Points</h3>
    <ul><li>Kaplan Fox investigating potential securities violations against Cellebrite (CLBT).</li><li>Q2 ARR $507.8M; ARR guidance cut midpoint by $15M.</li><li>CEO Tom Hogan replaced by Shiv Ramji; immediate effect.</li><li>Cellebrite stock down 29% to $10.80 on Aug 13.</li></ul>
  </section>

  <section data-block="companies-mentioned">
    <h3>Companies Mentioned</h3>
    <ul><li><strong>Cellebrite DI Ltd. (CLBT)</strong>: Subject of securities investigation; potential material impact on stock and governance.</li><li><strong>Kaplan Fox &amp; Kilsheimer LLP (N/A)</strong>: Plaintiffs&#039; litigation firm issuing the investigation; could signal growing legal risk for CLBT.</li><li><strong>Tom Hogan (N/A)</strong>: Former CLBT CEO; replaced, indicating governance disruption.</li><li><strong>Shiv Ramji (N/A)</strong>: New CLBT CEO; leadership change may affect execution and strategic direction.</li></ul>
  </section>

  <section data-block="category">
    <h3>Legal</h3>
    <p>Category: Legal. The piece centers on a securities investigation and potential regulatory risk for CLBT, aligning with risk/impact assessment rather than core operating metrics.</p>
  </section>

  <section data-block="market-moving">
    <h3>Market-Moving</h3>
    <ul><li>CLBT likely to remain volatile as the investigation news persists.</li><li>ARR miss and leadership change could heighten governance concerns and funding risk.</li><li>Legal overhang may pressure multiple expansion and valuation.</li></ul>
  </section>

  <section data-block="key-facts">
    <h3>Key Facts</h3>
    <ul><li>Q2 ARR: $507.8 million.</li><li>ARR guidance cut by midpoint: ~ $15 million (lower end revealed previously $510-513M).</li><li>Delay cited: foreign entity permit requirement affecting cloud deals.</li><li>CEO change: Tom Hogan replaced by Shiv Ramji, effective immediately.</li><li>Stock reaction: down 29% to $10.80 on Aug 13, 2026.</li></ul>
  </section>

  <section data-block="trading-thesis">
    <h3>Trading Thesis</h3>
    <p>Bearish near-term upside risk until investigation clarity and ARR trajectory improve (1–3 quarters).</p>
  </section>
</section>


<p>New York, New York--(Newsfile Corp. - August 24, 2026) - <a href="https://api.newsfilecorp.com/redirect/N3vvniN7D7">Kaplan Fox &#38; Kilsheimer LLP</a> is investigating potential securities violations against Cellebrite DI Ltd. ("Cellebrite" or the "Company") (NASDAQ:<a class="ticker" href="https://www.benzinga.com/quote/CLBT">CLBT</a>).</p><p style="text-align: center;"><a href="https://api.newsfilecorp.com/redirect/XEOO2SPBG2">CLICK HERE TO RECEIVE MORE INFORMATION ABOUT THIS INVESTIGATION</a></p><p><b>If you are a Cellebrite investor and have suffered losses, or if you have information that could assist in the Cellebrite investigation, you may </b><a href="https://api.newsfilecorp.com/redirect/DOWW5FnQBE"><b>CLICK HERE</b></a><b> to contact us. You may also contact Kaplan Fox by emailing </b><a href="mailto:pmayer@kaplanfox.com"><b>pmayer@kaplanfox.com</b></a><b> or by calling (646) 315-9003.</b></p><p>On August 13, 2026, Cellebrite reported second-quarter results, including total Annual Recurring Revenue ("ARR") of $507.8 million, missing the lower end of the Company's previous projection for ARR in the range of $510 million to $513 million.  The Company also cut its full-year annual recurring revenue guidance by roughly $15 million at the midpoint and cited "a foreign entity permit requirement, which is applied to cloud technology" that delayed certain deals.  Cellebrite simultaneously announced an abrupt CEO change, replacing CEO Tom Hogan with Shiv Ramji, effective immediately. </p><p>Following this news, the price of Cellebrite stock fell $4.45 per share, or 29%, to close at $10.80 per share August 13, 2026.</p><p><b>WHY CONTACT KAPLAN FOX?</b></p><p>Kaplan Fox &#38; Kilsheimer LLP is a nationally recognized law firm focused on complex litigation, with offices in New York, Oakland, Los Angeles, Chicago, and New Jersey. Founded in 1956, the firm has spent more than 50 years prosecuting securities, antitrust, and consumer protection actions in federal and state courts nationwide, recovering more than $10 billion for clients and the classes it has represented.</p><p>Kaplan Fox is widely regarded as one of the nation's premier plaintiffs' securities litigation firms and has received recognition from Chambers and Partners, Benchmark Litigation, Super Lawyers, and Lawdragon. Serving as lead or co-lead counsel in many landmark cases, the firm has secured some of the largest recoveries in the history of securities litigation, including a $2.425 billion recovery on behalf of Bank of America shareholders in <i>In re Bank of America</i>-the largest recovery ever obtained for claims under Section 14(a) of the Securities Exchange Act-$800 million recovered for the Arkansas Teacher Retirement System and other pension funds in <i>ATRS v. Allianz Global Investors</i>, and a $475 million settlement in <i>In re Merrill Lynch</i>.</p><p>For decades, Kaplan Fox has represented public pension funds, institutional investors, businesses, and individuals in high-stakes litigation. Through its successful advocacy and precedent-setting victories, the firm has helped shape important areas of securities and corporate law while advancing accountability and protecting investor interests.</p><p>This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Past results do not guarantee future outcomes.</p><p>If you have any questions about this investigation, please contact:</p><div id="contactInfo"><p><b>CONTACT:</b><br />Pamela A. Mayer<br /><a href="https://api.newsfilecorp.com/redirect/rpLLACq32L">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />800 Third Avenue, 38th Floor<br />New York, New York 10022<br />(646) 315-9003<br /><a href="mailto:pmayer@kaplanfox.com">pmayer@kaplanfox.com</a></p><p>Laurence D. King<br /><a href="https://api.newsfilecorp.com/redirect/VvLLEFYwDj">KAPLAN FOX &#38; KILSHEIMER LLP</a><br />1999 Harrison Street, Suite 1501<br />Oakland, California 94612<br />(415) 772-4704<br /><a href="mailto:lking@kaplanfox.com">lking@kaplanfox.com</a></p></div><p>Contacting or submitting information to Kaplan Fox &#38; Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.</p><p><a href="https://api.newsfilecorp.com/redirect/zA00ehyAaa">https://www.kaplanfox.com/case/cellebrite-di-ltd-investigation-learn-more-now/</a></p><p id="corporateNewsLogoContainer"><img src="https://images.newsfilecorp.com/files/12532/311009_54f395c174331b48_logo.jpg" id="corporateNewsLogo" alt="Corporate Logo" /></p><p id="corporateLinkBack">To view the source version of this press release, please visit <a href="https://api.newsfilecorp.com/redirect/4YGGLcWmqq">https://www.newsfilecorp.com/release/311009</a></p><p><img src="https://api.newsfilecorp.com/newsinfo/311009/197" alt="" /></p>

Kaplan Fox & Kilsheimer LLP is investigating potential securities violations at Cellebrite (CLBT) following a Q2 miss and governance shift. Cellebrite reported ARR of $507.8 million and cut full-year ARR guidance by about $15 million, while appointing Shiv Ramji as CEO. The combination of regulatory risk and leadership upheaval could pressure CLBT's valuation in the near term.

News insight

Kaplan Fox Notifies Cellebrite DI Ltd. (CLBT) Investors of a Securities Investigation into the Company

AI summary

Sentiment rationale

Key facts

Legal